Schwab Andrew J.'s Form 4 filing
Enliven Therapeutics, Inc. (ELVN) · filed Aug 28, 2023
- Accession no.
- 0001209191-23-047514
- Filed
- Aug 28, 2023, 4:20 PM ET
- Trade date
- Aug 24, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $7.04M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schwab Andrew J.CIK 0001598549 | 10% Owner |
| Parmar KushCIK 0001664281 | 10% Owner |
| 5AM Opportunities I, L.P.CIK 0001753000 | 10% Owner |
| 5AM Ventures VI, L.P.CIK 0001753037 | 10% Owner |
| 5AM Opportunities I (GP), LLCCIK 0001790778 | 10% Owner |
| 5AM Partners VI, LLCCIK 0001829051 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 2 transactions in Table I.